drugset / Trial / NCT01107964
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
Completed
27 enrolled
Milton S. Hershey Medical Center
GlaxoSmithKline · collabThe American Society of Cataract and Refractive Surgery Foundation · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline, Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with lissamine green, and fluorescein tear break-up time) when compared to administration of placebo.
Timeline
- Start
- 2010-07
- Primary completion
- 2014-08
- Completion
- 2015-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lovaza | Other / unclassified | 1 g | Oral |